Close Menu

NEW YORK – The US Food and Drug Administration has updated its requirements for molecular diagnostic developers seeking Emergency Use Authorization for COVID-19 tests to include the use of actual positive specimens.

In the eighth of its weekly virtual town hall meetings on Wednesday, Timothy Stenzel, director of the agency's office if in vitro diagnostics and radiological health, said going forward FDA will require developers to use such specimens as part of the validation process.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.